These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34976500)

  • 1. Helicobacter pylori Resistance to Triple Therapy in a Multicultural Population in New York City.
    Fernandez-Perez S; Velazco G; Lenik JM; Achuo-Egbe Y; Harley J
    Cureus; 2021 Nov; 13(11):e19883. PubMed ID: 34976500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.
    Tanabe H; Yoshino K; Ando K; Nomura Y; Ohta K; Satoh K; Ichiishi E; Ishizuka A; Otake T; Kohgo Y; Fujiya M; Okumura T
    Ann Clin Microbiol Antimicrob; 2018 Jun; 17(1):29. PubMed ID: 29950163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
    Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
    World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimum duration of regimens for Helicobacter pylori eradication.
    Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance.
    Park CS; Lee SM; Park CH; Koh HR; Jun CH; Park SY; Lee WS; Joo YE; Kim HS; Choi SK; Rew JS
    Am J Gastroenterol; 2014 Oct; 109(10):1595-602. PubMed ID: 25091062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eradication Rate of
    Liu RP; Romero R; Sarosiek J; Dodoo C; Dwivedi AK; Zuckerman MJ
    South Med J; 2018 Jan; 111(1):51-55. PubMed ID: 29298370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial susceptibility testing before first-line treatment for
    Cosme A; Montes M; Ibarra B; Tamayo E; Alonso H; Mendarte U; Lizasoan J; Herreros-Villanueva M; Bujanda L
    World J Gastroenterol; 2017 May; 23(18):3367-3373. PubMed ID: 28566898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Helicobacter pylori antimicrobial resistance on the outcome of 1-week lansoprazole-based triple therapy.
    Huang AH; Sheu BS; Yang HB; Huang CC; Wu JJ; Lin XZ
    J Formos Med Assoc; 2000 Sep; 99(9):704-9. PubMed ID: 11000734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.
    Luther J; Higgins PD; Schoenfeld PS; Moayyedi P; Vakil N; Chey WD
    Am J Gastroenterol; 2010 Jan; 105(1):65-73. PubMed ID: 19755966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of PPI, levofloxacin and amoxicillin in the eradication of Helicobacter pylori compared to conventional triple therapy at a Venezuelan hospital.
    Dib J; Alvarez B; Mendez L; Cruz ME
    Arab J Gastroenterol; 2013 Sep; 14(3):123-5. PubMed ID: 24206741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Three 7-Day Pantoprazole-Based Helicobacter pylori Eradication Regimens in a Mexican Population with High Metronidazole Resistance.
    Dehesa M; Larisch J; Dibildox M; Di Silvio M; Lopez LH; Ramirez-Barba E; Torres J
    Clin Drug Investig; 2002; 22(2):75-85. PubMed ID: 23315395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
    Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
    Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of quadruple regimen of clarithromycin added to metronidazole-containing triple therapy against Helicobacter pylori infection following clarithromycin-containing triple-therapy failure.
    Ueki N; Miyake K; Kusunoki M; Shindo T; Kawagoe T; Futagami S; Tsukui T; Inagaki H; Sakamoto C
    Helicobacter; 2009 Apr; 14(2):91-9. PubMed ID: 19298336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.
    Lee JM; Breslin NP; Hyde DK; Buckley MJ; O'Morain CA
    Aliment Pharmacol Ther; 1999 Apr; 13(4):489-96. PubMed ID: 10215733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: a prospective study.
    Pilotto A; Franceschi M; Rassu M; Leandro G; Bozzola L; Furlan F; Di Mario F
    Dig Liver Dis; 2000 Nov; 32(8):667-72. PubMed ID: 11142574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in the eradication rates of Helicobacter pylori infection for eleven years.
    Yoon JH; Baik GH; Sohn KM; Kim DY; Kim YS; Suk KT; Kim JB; Kim DJ; Kim JB; Shin WG; Kim HY; Baik IH; Jang HJ
    World J Gastroenterol; 2012 Dec; 18(45):6628-34. PubMed ID: 23236238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies.
    Georgopoulos SD; Ladas SD; Karatapanis S; Triantafyllou K; Spiliadi C; Mentis A; Artikis V; Raptis SA
    Aliment Pharmacol Ther; 2002 Mar; 16(3):569-75. PubMed ID: 11876712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced symptoms and need for antisecretory therapy in veterans 3 years after Helicobacter pylori eradication with ranitidine bismuth citrate/amoxicillin/clarithromycin.
    Sontag SJ; O'Connell S; Schnell T; Chejfec G; Seidel J; Sonnenberg A
    Am J Gastroenterol; 2001 May; 96(5):1390-5. PubMed ID: 11374672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
    Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H
    Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.
    Molina-Infante J; Pazos-Pacheco C; Vinagre-Rodriguez G; Perez-Gallardo B; Dueñas-Sadornil C; Hernandez-Alonso M; Gonzalez-Garcia G; Mateos-Rodriguez JM; Fernandez-Bermejo M; Gisbert JP
    Helicobacter; 2012 Aug; 17(4):269-76. PubMed ID: 22759326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.